Mixed Martial Arts Group Limited (NYSE American: MMA) announced an exclusive marketing partnership with The Precision Peptide Company Inc. (CSE: BPC; OTCQB: PNGAF) to sell peptide recovery products across its global combat sports network.

Under the agreement, MMA.INC will receive 50% of net revenue from sales generated through its platform during the first twelve months, followed by 25% of net revenue for the remainder of the partnership term. The company will market Precision's U.S.-manufactured and third-party tested peptide products through its ecosystem of platforms including TrainAlta, BJJLink, and MixedMartialArts.com.

The partnership can be terminated by either party with 30 days written notice. Following termination, MMA.INC will continue receiving its revenue share on sales to customers it referred for an additional twelve months.

MMA.INC operates what it describes as one of the world's largest digitally connected combat sports ecosystems, with approximately 530,000 user profiles, more than 75,000 active students and over 800 verified gyms globally across 22 countries.

All peptide products sold under the partnership will be manufactured in the United States and comply with U.S. Food and Drug Administration requirements and other applicable regulatory standards, according to the companies.

"This partnership establishes an entirely new commercial vertical for MMA.INC and positions the Company at the intersection of several major long-term growth trends, including recovery therapeutics, longevity, preventative health and regulated peptide commercialization," said Nick Langton, founder and CEO of MMA.INC.

The information was provided in a press release statement from Mixed Martial Arts Group Limited.